XML 50 R53.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Revenue Earned under Agreement with GSK (Detail) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2012
National Institute Of Allergy And Infectious Diseases
Dec. 31, 2011
National Institute Of Allergy And Infectious Diseases
Dec. 31, 2010
National Institute Of Allergy And Infectious Diseases
Dec. 31, 2008
Glaxo, Smith, Kline
Dec. 31, 2012
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Dec. 31, 2010
Glaxo, Smith, Kline
Sep. 30, 2006
Astra Zeneca
Dec. 31, 2012
Astra Zeneca
Dec. 31, 2011
Astra Zeneca
Dec. 31, 2010
Astra Zeneca
Dec. 31, 2008
Astra Zeneca
Dec. 31, 2012
National Institutes of Health
Dec. 31, 2011
National Institutes of Health
Dec. 31, 2010
National Institutes of Health
Product Information [Line Items]                                                    
Initial payment                             $ 10,000 $ 1,428 $ 1,428 $ 1,428 $ 10,000 $ 720 $ 120 $ 10,778        
Milestone revenue                                 15,000     2,462 642 3,315 4,500      
Total 1,806 2,874 2,684 2,350 11,427 1,174 7,269 1,744 9,714 21,614 23,950         1,428 16,428 1,428   3,182 762 14,093        
Grant revenue                 $ 3,939 $ 3,110 $ 3,940 $ 3,571 $ 2,730 $ 3,197                   $ 368 $ 380 $ 743